Mark Erlander insider trades
Open-market stock purchases and sales by Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc, from SEC Form 4 filings since Jan 4, 2016.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -25%.
Recent trades
No open-market trades in the last 12 months.